Last reviewed · How we verify
NCT01421706: sibu
Effects of Clopidogrel and Clarithromycin on the Disposition of Sibutramine and Its Active Metabolites M1 and M2 in Relation to CYP2B6*6 Polymorphism
Phase 1 trial testing Sibutramine-clopidogrel in Healthy in 20 participants. Completed in 1 July 2009.
1 July 2009
Quick facts
| Lead sponsor | Inje University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Enrollment | 20 |
| Start date | 1 July 2008 |
| Primary completion | 1 July 2009 |
| Estimated completion | 1 July 2009 |
Drugs / interventions tested
- Sibutramine-clopidogrel — full drug profile →
- sibutramine-Clarithromycin — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Inje University
Who can join
Adults 19 to 55, male only, with Healthy. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
effects of clopidogrel and clarithromycin on the disposition of sibutramine
Time frame: one year
the effects of clopidogrel and clarithromycin on the disposition of sibutramine and its two active metabolites M1 and M2 in vivo in relation to CYP2B6\*6 genetic polymorphism have been evaluated in Korean healthy subjects.
Sponsor's own description
Effects of clopidogrel and clarithromycin on the oral disposition of sibutramine in healthy subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01421706
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Inje University trials
Trials by the same sponsor.
- NCT07318428 — AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma · NA · enrolling by invitation
- NCT05636189 — Effect of Prewarming During Induction of General Anesthesia Combined With Warmed Intravenous Fluid on Core Temperature. · NA · completed
- NCT05766644 — App-based Education Program for CKD · NA · unknown
- NCT05514405 — Effect of Remimazolam and Propofol on Postoperative Delirium · NA · recruiting
- NCT05439057 — Effect of Remimazolam on Postoperative Nausea and Vomiting · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01421706 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Inje University
- Last refreshed: 16 September 2012
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01421706.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing